Treatment of osteoporosis and autoimmune disease with astrogorgiadiol
US7345035B2 · kind B2 · utility
1Cited by
0References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 28, 2003 |
| Grant date | Mar 18, 2008 |
| Priority date | — |
| Expiry date | Oct 25, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/44
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides methods of downregulating mRNA encoding osteopontin comprising administering to a cell or mammal an amount of astrogorgiadiol effective to downregulate production of mRNA encoding osteopontin. The invention also provides methods of treating osteoporosis and autoimmune disease comprising administering to a patient in need of such treatment a therapeutically effective amount of astrogorgiadiol. Pharmaceutical compositions comprising astrogorgiadiol and a pharmaceutically acceptable carrier or diluent are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.